NVG-291
Spinal Cord Injury
Key Facts
About NervGen Pharma
NervGen Pharma is pioneering a novel approach to treating nervous system damage by targeting the body's natural repair mechanisms. The company's core technology focuses on overcoming inhibitory signals in the damaged nervous system to enable regeneration and functional recovery. Its lead asset, NVG-291, is advancing through clinical trials with promising early data, positioning NervGen as a key player in the neuroregeneration field. The company's strategy targets multiple high-need neurological conditions with significant unmet medical need.
View full company profileAbout NervGen Pharma
NervGen Pharma is pioneering a novel approach to treating nervous system damage by targeting the body's natural repair mechanisms. The company's core technology focuses on overcoming inhibitory signals in the damaged nervous system to enable regeneration and functional recovery. Its lead asset, NVG-291, is advancing through clinical trials with promising early data, positioning NervGen as a key player in the neuroregeneration field. The company's strategy targets multiple high-need neurological conditions with significant unmet medical need.
View full company profileAbout NervGen Pharma
NervGen Pharma is pioneering a novel approach to treating nervous system damage by targeting the body's natural repair mechanisms. The company's core technology focuses on overcoming inhibitory signals in the damaged nervous system to enable regeneration and functional recovery. Its lead asset, NVG-291, is advancing through clinical trials with promising early data, positioning NervGen as a key player in the neuroregeneration field. The company's strategy targets multiple high-need neurological conditions with significant unmet medical need.
View full company profileAbout NervGen Pharma
NervGen Pharma is pioneering a novel approach to treating nervous system damage by targeting the body's natural repair mechanisms. The company's core technology focuses on overcoming inhibitory signals in the damaged nervous system to enable regeneration and functional recovery. Its lead asset, NVG-291, is advancing through clinical trials with promising early data, positioning NervGen as a key player in the neuroregeneration field. The company's strategy targets multiple high-need neurological conditions with significant unmet medical need.
View full company profile